ORIGINAL RESEARCH article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1577590
This article is part of the Research TopicAutoimmune Diseases: from molecular mechanisms to therapy developmentView all 9 articles
Profiling of fecal analytes as a potential biomarker in rheumatoid arthritis
Provisionally accepted
- 1Nanjing Medical University, Nanjing, China
- 2Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Loss of gut barrier integrity has been observed in rheumatoid arthritis (RA).While systemic inflammation in RA has been extensively investigated, intestinal-specific inflammatory processes remain poorly understood. This study is designed to identify a novel biomarker panel combining fecal cytokine profiles with gut barrier biomarkers to discriminate RA patients with varying disease progression.Methods: Feces (Fc) and plasma (Pl) were obtained from 62 Naive RA patients (NA), 47 remission RA patients (RE), 28 difficult-to-treat RA patients(D2T), and 70 healthy controls (HC). A panel of 12 cytokines and gut barrier markers, including intestinal Fatty-Acid-Binding Protein-2 (FABP2), zonulin, Hypoxia-Inducible Factor-2α (HIF-2α), D-lactate, LBP and fecal calprotectin (FCAL), was quantified by ELISA. Statistical integration with clinical parameters was performed using univariate and multivariate approaches.Results: NA and D2T patients demonstrated marked elevations in fecal pro-inflammatory
Keywords: Rheumatoid arthritis, Cytokines, biomarkers, intestinal inflammation, intestinal barrier function
Received: 16 Feb 2025; Accepted: 29 Apr 2025.
Copyright: © 2025 ZhiYi, YuJia, YaChen and Jianmin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xie Jianmin, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210011, Jiangsu Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.